Movement Alert｜PHARMARON Rises 3.59% in Regular Trading, CXO Sector Strengthens Ahead of H1 Results Review

Market Focus08-13

On August 13, PHARMARON rose 3.59% in regular trading, trading at HK$30.0/share, with turnover of HK$35.25 million.

On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its interim results for the first half of the year. The company previously guided H1 revenue of RMB 7.47 billion to RMB 7.67 billion, representing year-over-year growth of 16% to 19%, with newly signed orders rising over 30% and small-molecule CDMO new orders surging more than 50%.

Meanwhile, the CXO sector continues to strengthen broadly. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit growth of 29.43%, reinforcing the sector's improving fundamentals and driving valuation recovery across peers. On the same day, WuXi AppTec gained 1.36%, WuXi Biologics rose 0.57%, and GenScript Biotech advanced 2.33%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136123902?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136123902","market":"us","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.59% in Regular Trading, CXO Sector Strengthens Ahead of H1 Results Review","media":"Market Focus","content":"<p><p>On August 13, PHARMARON rose 3.59% in regular trading, trading at HK$30.0/share, with turnover of HK$35.25 million.</p><p>On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its interim results for the first half of the year. The company previously guided H1 revenue of RMB 7.47 billion to RMB 7.67 billion, representing year-over-year growth of 16% to 19%, with newly signed orders rising over 30% and small-molecule CDMO new orders surging more than 50%.</p><p>Meanwhile, the CXO sector continues to strengthen broadly. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit growth of 29.43%, reinforcing the sector's improving fundamentals and driving valuation recovery across peers. On the same day, WuXi AppTec gained 1.36%, WuXi Biologics rose 0.57%, and GenScript Biotech advanced 2.33%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.59% in Regular Trading, CXO Sector Strengthens Ahead of H1 Results Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.59% in Regular Trading, CXO Sector Strengthens Ahead of H1 Results Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-13 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 13, PHARMARON rose 3.59% in regular trading, trading at HK$30.0/share, with turnover of HK$35.25 million.</p><p>On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its interim results for the first half of the year. The company previously guided H1 revenue of RMB 7.47 billion to RMB 7.67 billion, representing year-over-year growth of 16% to 19%, with newly signed orders rising over 30% and small-molecule CDMO new orders surging more than 50%.</p><p>Meanwhile, the CXO sector continues to strengthen broadly. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit growth of 29.43%, reinforcing the sector's improving fundamentals and driving valuation recovery across peers. On the same day, WuXi AppTec gained 1.36%, WuXi Biologics rose 0.57%, and GenScript Biotech advanced 2.33%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1136123902","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136123902","pubTimestamp":1786585157,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 13, PHARMARON rose 3.59% in regular trading, trading at HK$30.0/share, with turnover of HK$35.25 million.On the news front, the company's board of directors is scheduled to convene on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨3.59%，CXO板块在上半年业绩审查前走强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 13, PHARMARON rose 3.59% in regular trading, trading at HK$30.0/share, with turnover of HK$35.25 million.On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its interim results for the first half of the year. The company previously guided H1 revenue of RMB 7.47 billion to RMB 7.67 billion, representing year-over-year growth of 16% to 19%, with newly signed orders rising over 30% and small-molecule CDMO new orders surging more than 50%.Meanwhile, the CXO sector continues to strengthen broadly. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit growth of 29.43%, reinforcing the sector's improving fundamentals and driving valuation recovery across peers. On the same day, WuXi AppTec gained 1.36%, WuXi Biologics rose 0.57%, and GenScript Biotech advanced 2.33%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136123902","isCrawlerRequest":true}